Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
about
Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.Clinical applications of virosomes in cancer immunotherapy.Identification of genes required for protection from doxorubicin by a genome-wide screen in Saccharomyces cerevisiae.
P2860
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Optimal therapy for platinum-r ...... cin, gemcitabine or topotecan?
@ast
Optimal therapy for platinum-r ...... cin, gemcitabine or topotecan?
@en
type
label
Optimal therapy for platinum-r ...... cin, gemcitabine or topotecan?
@ast
Optimal therapy for platinum-r ...... cin, gemcitabine or topotecan?
@en
prefLabel
Optimal therapy for platinum-r ...... cin, gemcitabine or topotecan?
@ast
Optimal therapy for platinum-r ...... cin, gemcitabine or topotecan?
@en
P2093
P2860
P356
P1476
Optimal therapy for platinum-r ...... cin, gemcitabine or topotecan?
@en
P2093
D Pectasides
M Pectasides
T Economopoulos
P2860
P304
P356
10.1517/14656566.7.8.975
P407
P577
2006-06-01T00:00:00Z